Interventions To Attenuate Vascular Calcification Progression in Chronic Kidney Disease: A Systematic Review of Clinical Trials

Vascular calcification is associated with cardiovascular morbidity and mortality in people with CKD. Evidence-based interventions that may attenuate its progression in CKD remain uncertain. We conducted a systematic review of prospective clinical trials of interventions to attenuate vascular calcifi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American Society of Nephrology 2022-05, Vol.33 (5), p.1011-1032
Hauptverfasser: Xu, Chelsea, Smith, Edward R, Tiong, Mark K, Ruderman, Irene, Toussaint, Nigel D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1032
container_issue 5
container_start_page 1011
container_title Journal of the American Society of Nephrology
container_volume 33
creator Xu, Chelsea
Smith, Edward R
Tiong, Mark K
Ruderman, Irene
Toussaint, Nigel D
description Vascular calcification is associated with cardiovascular morbidity and mortality in people with CKD. Evidence-based interventions that may attenuate its progression in CKD remain uncertain. We conducted a systematic review of prospective clinical trials of interventions to attenuate vascular calcification in people with CKD, compared with placebo, another comparator, or standard of care. We included prospective clinical trials (randomized and nonrandomized) involving participants with stage 3-5D CKD or kidney transplant recipients; the outcome was vascular calcification measured using radiologic methods. Quality of evidence was determined by the Cochrane risk of bias assessment tool and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) method. There were 77 trials (63 randomized) involving 6898 participants eligible for inclusion (median sample size, 50; median duration, 12 months); 58 involved participants on dialysis, 15 involved individuals with nondialysis CKD, and 4 involved kidney transplant recipients. Risk of bias was moderate over all. Trials involving magnesium and sodium thiosulfate consistently showed attenuation of vascular calcification. Trials involving intestinal phosphate binders, alterations in dialysate calcium concentration, vitamin K therapy, calcimimetics, and antiresorptive agents had conflicting or inconclusive outcomes. Trials involving vitamin D therapy and HMG-CoA reductase inhibitors did not demonstrate attenuation of vascular calcification. Mixed results were reported for single studies of exercise, vitamin E-coated or high-flux hemodialysis membranes, interdialytic sodium bicarbonate, SNF472, spironolactone, sotatercept, nicotinamide, and oral activated charcoal. Currently, there are insufficient or conflicting data regarding interventions evaluated in clinical trials for mitigation of vascular calcification in people with CKD. Therapy involving magnesium or sodium thiosulfate appears most promising, but evaluable studies were small and of short duration.
doi_str_mv 10.1681/asn.2021101327
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9063901</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2635238882</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-56dc48dc8534e3c782c7a3b647c09d2f044f1c523e4f269c4fb8e443285bdae23</originalsourceid><addsrcrecordid>eNpVkUtP3DAUha2qCOjAliXysptM_Yrj6QJpFFpAoBaVabeWx7kBVxl7sJOpZsVfxxGUx-oe6X73eRA6omRKpaJfTPJTRhilhHJWfUD7tOS84KIkH7MmQhZSVnwPfUrpLyG0ZFW1i_Z4yTJdiX30cOF7iBvwvQs-4UXA874HP5ge8B-T7NCZiGvTWdc6a0YIX8dwGyGlUTuP67sYvLP40jUetvjUJTAJvuI5vtmmHla5yOJfsHHwD4cW153LtOnwIjrTpQO00-YAh89xgn5__7aoz4urn2cX9fyqsKKUfVHKxgrVWFVyAdxWitnK8KUUlSWzhrVEiJbafBWIlsmZFe1SgRCcqXLZGGB8gk6e-q6H5Qoamw-OptPr6FYmbnUwTr_PeHenb8NGz4jks_zcCfr83CCG-wFSr1cuWeg64yEMSTM5PlUpNc6aPqE2hpQitC9jKNGja3p-80O_upYLjt8u94L_t4k_ApNelZ8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2635238882</pqid></control><display><type>article</type><title>Interventions To Attenuate Vascular Calcification Progression in Chronic Kidney Disease: A Systematic Review of Clinical Trials</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Xu, Chelsea ; Smith, Edward R ; Tiong, Mark K ; Ruderman, Irene ; Toussaint, Nigel D</creator><creatorcontrib>Xu, Chelsea ; Smith, Edward R ; Tiong, Mark K ; Ruderman, Irene ; Toussaint, Nigel D</creatorcontrib><description>Vascular calcification is associated with cardiovascular morbidity and mortality in people with CKD. Evidence-based interventions that may attenuate its progression in CKD remain uncertain. We conducted a systematic review of prospective clinical trials of interventions to attenuate vascular calcification in people with CKD, compared with placebo, another comparator, or standard of care. We included prospective clinical trials (randomized and nonrandomized) involving participants with stage 3-5D CKD or kidney transplant recipients; the outcome was vascular calcification measured using radiologic methods. Quality of evidence was determined by the Cochrane risk of bias assessment tool and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) method. There were 77 trials (63 randomized) involving 6898 participants eligible for inclusion (median sample size, 50; median duration, 12 months); 58 involved participants on dialysis, 15 involved individuals with nondialysis CKD, and 4 involved kidney transplant recipients. Risk of bias was moderate over all. Trials involving magnesium and sodium thiosulfate consistently showed attenuation of vascular calcification. Trials involving intestinal phosphate binders, alterations in dialysate calcium concentration, vitamin K therapy, calcimimetics, and antiresorptive agents had conflicting or inconclusive outcomes. Trials involving vitamin D therapy and HMG-CoA reductase inhibitors did not demonstrate attenuation of vascular calcification. Mixed results were reported for single studies of exercise, vitamin E-coated or high-flux hemodialysis membranes, interdialytic sodium bicarbonate, SNF472, spironolactone, sotatercept, nicotinamide, and oral activated charcoal. Currently, there are insufficient or conflicting data regarding interventions evaluated in clinical trials for mitigation of vascular calcification in people with CKD. Therapy involving magnesium or sodium thiosulfate appears most promising, but evaluable studies were small and of short duration.</description><identifier>ISSN: 1046-6673</identifier><identifier>EISSN: 1533-3450</identifier><identifier>DOI: 10.1681/asn.2021101327</identifier><identifier>PMID: 35232774</identifier><language>eng</language><publisher>United States: American Society of Nephrology</publisher><subject>Clinical Research ; Female ; Humans ; Magnesium ; Male ; Prospective Studies ; Renal Dialysis ; Renal Insufficiency, Chronic - drug therapy ; Renal Insufficiency, Chronic - therapy ; Vascular Calcification - etiology</subject><ispartof>Journal of the American Society of Nephrology, 2022-05, Vol.33 (5), p.1011-1032</ispartof><rights>Copyright © 2022 by the American Society of Nephrology.</rights><rights>Copyright © 2022 by the American Society of Nephrology 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-56dc48dc8534e3c782c7a3b647c09d2f044f1c523e4f269c4fb8e443285bdae23</citedby><cites>FETCH-LOGICAL-c456t-56dc48dc8534e3c782c7a3b647c09d2f044f1c523e4f269c4fb8e443285bdae23</cites><orcidid>0000-0002-2651-1787 ; 0000-0001-9348-4638</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063901/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063901/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35232774$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xu, Chelsea</creatorcontrib><creatorcontrib>Smith, Edward R</creatorcontrib><creatorcontrib>Tiong, Mark K</creatorcontrib><creatorcontrib>Ruderman, Irene</creatorcontrib><creatorcontrib>Toussaint, Nigel D</creatorcontrib><title>Interventions To Attenuate Vascular Calcification Progression in Chronic Kidney Disease: A Systematic Review of Clinical Trials</title><title>Journal of the American Society of Nephrology</title><addtitle>J Am Soc Nephrol</addtitle><description>Vascular calcification is associated with cardiovascular morbidity and mortality in people with CKD. Evidence-based interventions that may attenuate its progression in CKD remain uncertain. We conducted a systematic review of prospective clinical trials of interventions to attenuate vascular calcification in people with CKD, compared with placebo, another comparator, or standard of care. We included prospective clinical trials (randomized and nonrandomized) involving participants with stage 3-5D CKD or kidney transplant recipients; the outcome was vascular calcification measured using radiologic methods. Quality of evidence was determined by the Cochrane risk of bias assessment tool and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) method. There were 77 trials (63 randomized) involving 6898 participants eligible for inclusion (median sample size, 50; median duration, 12 months); 58 involved participants on dialysis, 15 involved individuals with nondialysis CKD, and 4 involved kidney transplant recipients. Risk of bias was moderate over all. Trials involving magnesium and sodium thiosulfate consistently showed attenuation of vascular calcification. Trials involving intestinal phosphate binders, alterations in dialysate calcium concentration, vitamin K therapy, calcimimetics, and antiresorptive agents had conflicting or inconclusive outcomes. Trials involving vitamin D therapy and HMG-CoA reductase inhibitors did not demonstrate attenuation of vascular calcification. Mixed results were reported for single studies of exercise, vitamin E-coated or high-flux hemodialysis membranes, interdialytic sodium bicarbonate, SNF472, spironolactone, sotatercept, nicotinamide, and oral activated charcoal. Currently, there are insufficient or conflicting data regarding interventions evaluated in clinical trials for mitigation of vascular calcification in people with CKD. Therapy involving magnesium or sodium thiosulfate appears most promising, but evaluable studies were small and of short duration.</description><subject>Clinical Research</subject><subject>Female</subject><subject>Humans</subject><subject>Magnesium</subject><subject>Male</subject><subject>Prospective Studies</subject><subject>Renal Dialysis</subject><subject>Renal Insufficiency, Chronic - drug therapy</subject><subject>Renal Insufficiency, Chronic - therapy</subject><subject>Vascular Calcification - etiology</subject><issn>1046-6673</issn><issn>1533-3450</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkUtP3DAUha2qCOjAliXysptM_Yrj6QJpFFpAoBaVabeWx7kBVxl7sJOpZsVfxxGUx-oe6X73eRA6omRKpaJfTPJTRhilhHJWfUD7tOS84KIkH7MmQhZSVnwPfUrpLyG0ZFW1i_Z4yTJdiX30cOF7iBvwvQs-4UXA874HP5ge8B-T7NCZiGvTWdc6a0YIX8dwGyGlUTuP67sYvLP40jUetvjUJTAJvuI5vtmmHla5yOJfsHHwD4cW153LtOnwIjrTpQO00-YAh89xgn5__7aoz4urn2cX9fyqsKKUfVHKxgrVWFVyAdxWitnK8KUUlSWzhrVEiJbafBWIlsmZFe1SgRCcqXLZGGB8gk6e-q6H5Qoamw-OptPr6FYmbnUwTr_PeHenb8NGz4jks_zcCfr83CCG-wFSr1cuWeg64yEMSTM5PlUpNc6aPqE2hpQitC9jKNGja3p-80O_upYLjt8u94L_t4k_ApNelZ8</recordid><startdate>202205</startdate><enddate>202205</enddate><creator>Xu, Chelsea</creator><creator>Smith, Edward R</creator><creator>Tiong, Mark K</creator><creator>Ruderman, Irene</creator><creator>Toussaint, Nigel D</creator><general>American Society of Nephrology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2651-1787</orcidid><orcidid>https://orcid.org/0000-0001-9348-4638</orcidid></search><sort><creationdate>202205</creationdate><title>Interventions To Attenuate Vascular Calcification Progression in Chronic Kidney Disease: A Systematic Review of Clinical Trials</title><author>Xu, Chelsea ; Smith, Edward R ; Tiong, Mark K ; Ruderman, Irene ; Toussaint, Nigel D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-56dc48dc8534e3c782c7a3b647c09d2f044f1c523e4f269c4fb8e443285bdae23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Clinical Research</topic><topic>Female</topic><topic>Humans</topic><topic>Magnesium</topic><topic>Male</topic><topic>Prospective Studies</topic><topic>Renal Dialysis</topic><topic>Renal Insufficiency, Chronic - drug therapy</topic><topic>Renal Insufficiency, Chronic - therapy</topic><topic>Vascular Calcification - etiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xu, Chelsea</creatorcontrib><creatorcontrib>Smith, Edward R</creatorcontrib><creatorcontrib>Tiong, Mark K</creatorcontrib><creatorcontrib>Ruderman, Irene</creatorcontrib><creatorcontrib>Toussaint, Nigel D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of the American Society of Nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xu, Chelsea</au><au>Smith, Edward R</au><au>Tiong, Mark K</au><au>Ruderman, Irene</au><au>Toussaint, Nigel D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interventions To Attenuate Vascular Calcification Progression in Chronic Kidney Disease: A Systematic Review of Clinical Trials</atitle><jtitle>Journal of the American Society of Nephrology</jtitle><addtitle>J Am Soc Nephrol</addtitle><date>2022-05</date><risdate>2022</risdate><volume>33</volume><issue>5</issue><spage>1011</spage><epage>1032</epage><pages>1011-1032</pages><issn>1046-6673</issn><eissn>1533-3450</eissn><abstract>Vascular calcification is associated with cardiovascular morbidity and mortality in people with CKD. Evidence-based interventions that may attenuate its progression in CKD remain uncertain. We conducted a systematic review of prospective clinical trials of interventions to attenuate vascular calcification in people with CKD, compared with placebo, another comparator, or standard of care. We included prospective clinical trials (randomized and nonrandomized) involving participants with stage 3-5D CKD or kidney transplant recipients; the outcome was vascular calcification measured using radiologic methods. Quality of evidence was determined by the Cochrane risk of bias assessment tool and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) method. There were 77 trials (63 randomized) involving 6898 participants eligible for inclusion (median sample size, 50; median duration, 12 months); 58 involved participants on dialysis, 15 involved individuals with nondialysis CKD, and 4 involved kidney transplant recipients. Risk of bias was moderate over all. Trials involving magnesium and sodium thiosulfate consistently showed attenuation of vascular calcification. Trials involving intestinal phosphate binders, alterations in dialysate calcium concentration, vitamin K therapy, calcimimetics, and antiresorptive agents had conflicting or inconclusive outcomes. Trials involving vitamin D therapy and HMG-CoA reductase inhibitors did not demonstrate attenuation of vascular calcification. Mixed results were reported for single studies of exercise, vitamin E-coated or high-flux hemodialysis membranes, interdialytic sodium bicarbonate, SNF472, spironolactone, sotatercept, nicotinamide, and oral activated charcoal. Currently, there are insufficient or conflicting data regarding interventions evaluated in clinical trials for mitigation of vascular calcification in people with CKD. Therapy involving magnesium or sodium thiosulfate appears most promising, but evaluable studies were small and of short duration.</abstract><cop>United States</cop><pub>American Society of Nephrology</pub><pmid>35232774</pmid><doi>10.1681/asn.2021101327</doi><tpages>22</tpages><orcidid>https://orcid.org/0000-0002-2651-1787</orcidid><orcidid>https://orcid.org/0000-0001-9348-4638</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1046-6673
ispartof Journal of the American Society of Nephrology, 2022-05, Vol.33 (5), p.1011-1032
issn 1046-6673
1533-3450
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9063901
source MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Clinical Research
Female
Humans
Magnesium
Male
Prospective Studies
Renal Dialysis
Renal Insufficiency, Chronic - drug therapy
Renal Insufficiency, Chronic - therapy
Vascular Calcification - etiology
title Interventions To Attenuate Vascular Calcification Progression in Chronic Kidney Disease: A Systematic Review of Clinical Trials
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T03%3A21%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interventions%20To%20Attenuate%20Vascular%20Calcification%20Progression%20in%20Chronic%20Kidney%20Disease:%20A%20Systematic%20Review%20of%20Clinical%20Trials&rft.jtitle=Journal%20of%20the%20American%20Society%20of%20Nephrology&rft.au=Xu,%20Chelsea&rft.date=2022-05&rft.volume=33&rft.issue=5&rft.spage=1011&rft.epage=1032&rft.pages=1011-1032&rft.issn=1046-6673&rft.eissn=1533-3450&rft_id=info:doi/10.1681/asn.2021101327&rft_dat=%3Cproquest_pubme%3E2635238882%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2635238882&rft_id=info:pmid/35232774&rfr_iscdi=true